Leonard Zehr, Author at BioTuesdays

Feature

Regenicin readying clinical trials of NovaDerm skin substitute

By Len Zehr Regenicin (OTC:RGIN) is completing validation of its NovaDerm skin substitute at a leading institute of technology in the U.S and plans to seek FDA approval to move into clinical trials in the second half of...

June 30, 2015

Feature

Inogen POCs represent paradigm shift in oxygen therapy

By Len Zehr Inogen (NASDAQ:INGN) is continuing to convert patients with lung disease from bulky oxygen tanks that need to be refilled every two weeks to its lightweight, portable oxygen concentrator (POC) that...

June 16, 2015

Feature

Titan Pharma Phase 3 data validate ProNeura technology

Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid addiction, validate the...

June 9, 2015

Feature

KAHR Medical on financing trail to develop dual signaling proteins

By Len Zehr Closely-held KAHR Medical of Israel is seeking to raise* as much as $10-million in the U.S. and Europe to continue development of its dual signaling proteins (DSPs), including KAHR-102, its lead drug...

June 2, 2015

Feature

Profound Medical seeking CE Mark for TULSA-PRO this year

Profound Medical, which is going public next week, figures that data from a 30-patient safety and feasibility study of its transurethral ultrasound ablation (TULSA) technology for minimally invasive treatment of...

May 26, 2015

Feature

Provectus taking novel path to treat cancer

By Len Zehr Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose...

May 19, 2015

Feature

T2 Biosystems to double sales force this year

By Len Zehr T2 Biosystems (NASDAQ:TTOO), which entered 2015 with seven direct sales reps, plans to add another eight during the year as it continues to roll out its first products: the T2Candida panel and T2Dx...

May 12, 2015

Feature

Axcelon leverages bacterial cellulose expertise with Nanoderm launch

By Len Zehr Axcelon Biopolymers, which plans to go public in the current quarter, has developed a sales and marketing plan with a leading wholesaler and its own sales team to gain maximum market share in Canada for its...

May 5, 2015

Feature

TransEnterix readying FDA filing of SurgiBot in mid-year

By Len Zehr TransEnterix (NYSE MKT:TRXC) plans to file for FDA approval in mid-year of its SurgiBot robotic platform to enhance minimally invasive laparoscopic surgery through a single surgical incision. “We anticipate...

April 28, 2015

Feature

In conversation with Dr. Shai Yarkoni

By Len Zehr As a co-founder and CEO of Cellect Biotechnology (TASE:CLBD), Dr. Shai Yarkoni has more than 15 years of clinical and management experience in the biopharmaceutical industry. He is the founder of five start...

April 21, 2015

Author - Leonard Zehr

Regenicin readying clinical trials of NovaDerm skin substitute

Inogen POCs represent paradigm shift in oxygen therapy

Titan Pharma Phase 3 data validate ProNeura technology

KAHR Medical on financing trail to develop dual signaling proteins

Profound Medical seeking CE Mark for TULSA-PRO this year

Provectus taking novel path to treat cancer

T2 Biosystems to double sales force this year

Axcelon leverages bacterial cellulose expertise with Nanoderm launch

TransEnterix readying FDA filing of SurgiBot in mid-year

In conversation with Dr. Shai Yarkoni

Subscribe